Dr. Charles M. Rudin highlighted new small cell lung cancer therapies, including T cell engagers, antibody-drug conjugates, ...

Future SCLC treatment may involve combining T-cell engagers with immune checkpoint inhibitors to enhance patient outcomes.

With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) ...

Please provide your email address to receive an email when new articles are posted on . Patients with limited-stage small-cell lung cancer had OS, PFS improvements on durvalumab compared with placebo ...

The Food and Drug Administration (FDA) has granted traditional approval to Imdelltra ® (tarlatamab-dlle) for the treatment of adults with extensive stage small cell lung cancer (ES-SCLC) with disease ...

Sac-TMT combined with Keytruda significantly improves progression-free survival in PD-L1-positive advanced non-small cell ...

New artificial intelligence technology is helping diagnose the U.S.’s most deadly cancer sooner, greatly improving the ...

The FDA has granted full approval to tarlatamab-dlle (Imdelltra) for the treatment of adult patients with extensive stage ...

Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer—the leading cause of cancer deaths worldwide—improved long-term survival overall compared with ...

Small cell lung cancer (SCLC) is rarer than non-small cell lung cancer (NSCLC) but tends to be more difficult to treat. SCLC can be more resistant and aggressive than other cancers, which can increase ...

Diagnosed with small-cell lung cancer at 28, Montessa Lee has defied the odds for nearly 20 years, surviving a disease with a historically low survival rate of just 5–10% according to the National ...

Please provide your email address to receive an email when new articles are posted on . Treatment with durvalumab improved PFS and OS compared with placebo. Incidence of grade 3 or grade 4 adverse ...